
    
      This study is a randomized, double-blind, placebo-controlled international phase 2 trial in
      patients with HRG+, HR+, HER2- metastatic breast cancer that has progressed following
      treatment with no more than 2 prior therapies, one of which must have been a CDK inhibitor.
      All patients will be screened for heregulin using central testing, and eligible patients will
      be randomized to receive either seribantumab + fulvestrant or placebo + fulvestrant. Disease
      status will be assessed according to RECIST v 1.1 to support the primary endpoint.
    
  